Found 18 articles for: "Dupilumab"
Cicatricial Ectropion in the Setting of IL-13 Inhibition
October 2026 | Volume 25 | Issue 10 | Case Reports | 971 | Copyright © October 2026
Introduction: Interleukin (IL)-13 is a key mediator of type 2 inflammation and an important therapeutic target in atopic dermatitis (AD). Although IL-4/IL-13 and IL-13 inhibitors...
Read MoreBiologics and Small-Molecule Inhibitors for the Treatment of Nummular Eczema: A Systematic Review
October 2026 | Volume 25 | Issue 10 | Original Article | 919 | Copyright © October 2026
Background: Nummular eczema (NE) is a chronic, pruritic dermatitis with substantial patient burden and no FDA-approved therapies. Emerging data suggest that biologics and small-m...
Read MoreFrom Bald to Bold: Reversal of Alopecia Totalis in an Adolescent Using Dupilumab Monotherapy
March 2026 | Volume 25 | Issue 3 | Case Reports | 273 | Copyright © March 2026
Introduction: Alopecia areata (AA) is an autoimmune condition marked by non-scarring, patchy hair loss of the scalp which progresses in <10% of cases to alopecia totalis (AT),...
Read MoreConnecting the Plaques: Exploring the Link Between Dupilumab and Cutaneous T-cell Lymphoma
November 2025 | Volume 24 | Issue 11 | Features | 1148 | Copyright © November 2025
Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months
October 2025 | Volume 24 | Issue 10 | Original Article | 996 | Copyright © October 2025
Background: Dupilumab has demonstrated benefits in patients with atopic dermatitis (AD), but there is limited information on real-world rates of dupilumab persistence and supplem...
Read MoreDupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups
February 2025 | Volume 24 | Issue 2 | Original Article | 167 | Copyright © February 2025
Background: Lichenification, common in moderate to severe atopic dermatitis (AD) at any age, is often difficult to treat. This analysis assessed dupilumab vs placebo in AD lichen...
Read MoreImprovement of Hailey-Hailey Disease Following Administration of Dupilumab
April 2025 | Volume 24 | Issue 4 | Case Reports | 410 | Copyright © April 2025
Hailey-Hailey disease (HHD) is a rare, chronic skin disorder characterized by recurrent inflammatory plaques with painful blisters, erosions, and macerations. We report a case of a 40-year-old fe...
Read MoreSuccessful Treatment of Keloids and Hypertrophic Scars With Systemic and Intralesional Dupilumab
December 2023 | Volume 22 | Issue 12 | Case Reports | 1220 | Copyright © December 2023
Keloids and hypertrophic scars negatively impact the quality of life for millions of people in the world. Unfortunately, though many thera-peutic approaches are used to treat scars, they are ofte...
Read MoreErythrodermic Bullous Pemphigoid in Skin of Color Treated With Dupilumab
July 2023 | Volume 22 | Issue 7 | Case Reports | 685 | Copyright © July 2023
Bullous pemphigoid (BP) is an autoimmune blistering disease that typically presents with pruritic, tense bullae in elderly patients.1 Several recognized presentations deviate from the ...
Read MoreDupilumab Induced Hair Regrowth in Alopecia Totalis
April 2023 | Volume 22 | Issue 4 | Case Reports | 410 | Copyright © April 2023
Alopecia Areata (AA) is an autoimmune process that results in varying degrees of hair loss. Currently, there is no single treatment that has proven to be efficacious in a large cohort of patients...
Read MoreA Qualitative Study on Dupilumab's Impact on Atopic Dermatitis Among Adolescent and Adult Patients
February 2023 | Volume 22 | Issue 2 | Original Article | 148 | Copyright © February 2023
Background: Atopic dermatitis (AD) is the most common inflammatory skin disease and dupilumab is US Food and Drug Administration-approved in both adult and pediatric AD patients.
Read MoreThe Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
October 2022 | Volume 21 | Issue 10 | Original Article | 1070 | Copyright © October 2022
Background: Approximately 30% to 40% of alopecia areata (AA) patients have atopic dermatitis. Studies suggest that antihistamines and dupilumab may be effective treatments; however, t...
Read MoreAnnual Trends in Medicare Part D Prescription Claims for Dupilumab 2017 to 2019
October 2022 | Volume 21 | Issue 10 | Editorials | 1138 | Copyright © October 2022
Disease control for moderate to severe atopic dermatitis (AD) has been primarily achieved with phototherapy and non-specific immunomodulators, cyclosporine, and methotrexate. These treatments have, ho...
Read MorePustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis
March 2022 | Volume 21 | Issue 3 | Case Reports | 311 | Copyright © March 2022
Dupilumab inhibits T-helper 2 (Th2)-driven inflammation cascade by blocking interleukin-4 (IL-4) and IL-13 signaling, which has been recognized to play a crucial role in the pathogenesis of atopic der...
Read MoreAnalysis of Reddit Reveals Dupilumab Questions Among Atopic Dermatitis Patients
March 2022 | Volume 21 | Issue 3 | Original Article | 292 | Copyright © March 2022
Background: Atopic dermatitis patients are turning to social media to seek guidance and source medical information. Reddit, the seventh most visited website in the US, contains the po...
Read MoreNonresponse and Progression of Diffuse Keloids to Dupilumab Therapy
February 2022 | Volume 21 | Issue 2 | Case Reports | 197 | Copyright © February 2022
Th2 cytokines, including IL-4 and IL-13, have been shown to increase TGFβ, promoting fibrosis. A recent study showed keloid improvement in one patient after administration of Dupilumab, an IL-4 r...
Read MoreChromate-Induced Allergic Contact Dermatitis Treated With Dupilumab
December 2021 | Volume 20 | Issue 12 | Case Reports | 1340 | Copyright © December 2021
Chromate causes persistent, difficult to treat irritant and allergic contact dermatitis in cement-handling occupational workers. When therapeutics such as topical corticosteroids, topical calcineurin ...
Read MoreSuccessful Treatment of Brunsting-Perry Cicatricial Pemphigoid With Dupilumab
October 2021 | Volume 20 | Issue 10 | Case Reports | 1113 | Copyright © October 2021
Brunsting-Perry is a rare variant of cicatricial pemphigoid, characterized by subepidermal bullae localized to the head and neck. Currently, treatment relies on non-specific immunosuppression, which i...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
